Filing identity and reporting period
Important mismatch: The request identifies Palvella Therapeutics, Inc. and 2013 Q3, but the supplied filing is for Marika Inc., a Nevada development-stage company, for the quarter ended March 31, 2014 (nine months ended March 31, 2014). The filing describes Marika as a shell company. Confirm the filing belongs to the intended issuer and period before relying on this summary.
Marika said it was formed to provide errand and concierge services through an online platform, but had no business operations or revenue as of the reporting date.
Financial results and condition
| Metric | Three months ended March 31, 2014 | Nine months ended March 31, 2014 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $1,544 | $9,504 |
| Net loss | $1,544 | $9,504 |
| Operating cash flow | $(294) | $(7,004) |
| Financing cash flow | $400 | $2,000 |
At March 31, 2014, cash and total assets were $196; current liabilities were $4,974, including $2,500 in accrued expenses and a $2,474 director loan. Stockholders’ deficit was $4,778, implying negative working capital of $4,778. The director loan is unsecured, non-interest-bearing, and due on demand. No interest or income taxes were paid. Gross or operating margins are not meaningful because there was no revenue.
The company had 5,000,000 common shares outstanding and reported basic and diluted loss per share of $0.00 (rounded). It reported no investing cash flows.
Changes versus prior information
Compared with June 30, 2013, cash fell from $5,200 to $196, liabilities rose from $474 to $4,974, and equity of $4,726 became a deficit of $4,778. The filing provides no prior-year comparable quarterly results; therefore, year-over-year operating changes cannot be assessed. For the nine months, the company recorded $9,504 of net loss and received $2,000 in director loans; the cash-flow statement reports $5,000 in stock proceeds from inception.
Outlook, risks, and notable disclosures
- Management said available working capital, anticipated cash flow, and further advances or debt were expected to fund operations for the next three months, but also stated that additional funding would be needed within 12 months to sustain and expand operations.
- No specific future financing arrangements were in place. Management anticipated raising capital, principally through equity, and warned that financing might not be available on acceptable terms or at all; equity or convertible debt could dilute shareholders or have senior rights.
- The financial statements and management discussion disclose substantial doubt about the company’s ability to continue as a going concern. The filing says the independent auditors’ review report included an explanatory paragraph to that effect.
- Management concluded disclosure controls and procedures were not effective as of March 31, 2014. It reported no material change in internal control over financial reporting during the quarter.
- The company had no employees other than its officer and director, no owned or leased property, and used office services provided without charge by an officer, with no obligation for that arrangement to continue.
- The filing reports no material subsequent events through May 2, 2014 and no known pending or threatened legal proceedings.
Key facts to verify
- Confirm the issuer and reporting period: the supplied document is Marika Inc.’s March 31, 2014 Form 10-Q, not a filing identified as Palvella Therapeutics, Inc. or 2013 Q3.
- Resolve the cash-flow disclosure inconsistency: the statement reports inception-to-date operating cash used of $7,004, while the MD&A text says inception-to-date operating cash flow was positive $7,004.
- Assess the company’s ability to fund operations, including the due-on-demand director loan, near-term liquidity, and lack of committed financing.
- Consider the disclosed going-concern doubt and ineffective disclosure controls when evaluating the financial statements and related disclosures.